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Abstract
There is an emerging need in clinical research to accurately predict patients disease status and
disease progression by optimally integrating multivariate clinical information. Clinical data is often
collected over time for multiple biomarkers of different types (e.g. continuous, binary, counts). In
this paper, we present a flexible and dynamic (time-dependent) discriminant analysis approach
in which multiple biomarkers of various types are jointly modelled for classification purposes by
the multivariate generalized linear mixed model. We propose a mixture of normal distributions
for the random effects to allow additional flexibility when modelling the complex correlation
between longitudinal biomarkers and to robustify the model and the classification procedure against
misspecification of the random effects distribution. These longitudinal models are subsequently used
in a multivariate time-dependent discriminant scheme to predict, at any time point, the probability of
belonging to a particular risk group. The methodology is illustrated using clinical data from patients
with epilepsy, where the aim is to identify patients who will not achieve remission of seizures within
a 5-year follow up period.
Keywords
Discriminant analysis, Multivariate generalized linear mixed model, Multivariate longitudinal data,
Random effects, Mixture distributions
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1 Introduction
In many clinical studies increasingly complex data is collected. The complexity of the data may be due
to its multivariate and longitudinal nature as measurements are often obtained for multiple biomarkers
over time. Data of this kind has a complex correlation structure with correlation, for each patient, between
measurements of a biomarker at different time points and between observed values of multiple biomarkers
at a single time point. An additional complication is that collected data is often of varying types, with
data being potentially continuous, counts, binary, or having multiple categories. Finally, the time points
at which biomarkers are measured may be different between biomarkers and between individuals for
a given biomarker.
Frequent clinical interest is in being able to classify patients into various groups corresponding to
severity of their disease status or disease progression, based on the evolution of biomarkers observed
over time. Our goal in this paper is to present a flexible and dynamic approach in which we use available
longitudinal data on multiple biomarkers of various types to accurately classify patients into groups (such
as diagnosis groups) in a discriminant analysis, and to do so as early as possible.
1.1 Clinical Motivation
We consider data from a study of patients with epilepsy to motivate our developments. We are interested
in being able to identify those patients who will not achieve remission from seizures within five years of
commencing treatment. For the purposes of this paper, this group of patients will be referred to as the
refractory group. By contrast, a patient is defined as being in remission if they have had a continuous
12 month period without any seizures at any point within five years from diagnosis. Our aim is to use
multivariate longitudinal clinical data from patients with epilepsy to identify, as early as possible, if
a particular patient belongs to the refractory group. Early classification would allow clinicians to try
alternative treatments with the hope of achieving adequate seizure control. Consequently, patients could
be spared some time on unsuitable treatment regimes and receive more effective, individualised treatment.
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Data was acquired from the Standard and New Antiepileptic Drugs (SANAD) study1;2 which involved
patients diagnosed with epilepsy between December 1999 and August 2004. Follow up data on these
patients is available up until January 2006. Here, 1 772 patients from the SANAD database are considered.
These patients have been followed-up sufficiently long to be known to belong to either the refractory
group or the remission group. For all patients, biomarkers of different type (continuous, counts and
binary) were collected over time. We remark that it is indeed possible for a patient to achieve remission
and then begin to have seizures again but this is not considered in our application. For simplicity, once
a patient achieves remission, they are considered as belonging to the remission group and all longitudinal
measurements subsequent to the visit at which remission was achieved are discarded.
Most patients had annual clinic visits, although in some cases the visits took place more often than
annually. Information about the number and type of seizures, as well as adverse events the patient has
experienced since the previous visit were collected. A number of baseline covariates were also collected
at the commencement of treatment (based on clinical relevance), including the patient’s age and gender,
epilepsy type, whether any family members had a history of seizures, whether the patient had learning or
neurological difficulties and to which arm of the SANAD study the patient had been assigned.
Out of the 1 772 patients investigated, 1 593 patients were in the remission group and 179 patients were
in the refractory group. The median (min, lower-quartile, upper-quartile, max) follow-up times (in days)
in the remission group was 710 (365, 480, 863, 1 821) whilst in the refractory group was 1 512 (1 463,
1 659, 1 825, 1 825). The difference in medians is easily explained due to the fact that patients who
achieve remission will generally be observed for less than five years (the majority achieving remission
within three years), whereas refractory patients need to be observed for at least four years to determine
the refractory status.
In the following, we will consider three longitudinal markers, namely whether a patient had seizures or
not since their last visit, which is binary, a transformation of the total number of seizures since their last
visit (using the transformation log(1 + total seizures)), which is treated as a continuous variable, and the
number of adverse events experienced since the last visit.
Figure 1 shows the change over time in the levels of each of the considered biomarkers for a sample
of 20 patients in each diagnostic group. As expected, in the remission group fewer patients experience
seizures since their last visit than in the refractory group. In the refractory group the likelihood of the
patient having experienced seizures since their last visit increases with time, whilst in the remission group
it decreases. For patients who achieve remission the number of seizures decreases over time, whereas
for refractory patients the number of seizures experienced remains high. It is interesting to note the most
dramatic increase/decrease occurs within the first 500 days of receiving treatment. In the refractory group,
the number of seizures experienced increases with time, with again, the main increase occurring during
the first 500 days. The difference between the two groups for the number of adverse events experienced is
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Figure 1. Observed longitudinal profiles of an indicator of whether a patient had seizures,
log(1 + total seizures) and number of adverse events experienced since the last visit for patients from the
Remission group (left column) and the Refractory group (right column). In both groups profiles of only 20
randomly selected patients are shown for clarity. Solid bold lines show LOESS smoothed profiles calculated
using data from all patients. The data indicating whether a patient had seizures or not have been vertically
jittered to aid interpretation.
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less noticeable. Initially both groups experience similar numbers of adverse events but as time increases
the refractory patients appear more likely to be experiencing more adverse events than the remission
patients.
In summary, Figure 1 highlights the challenges of the epilepsy data: having three longitudinal markers
of different type, measured at different time points within and across subjects. The differences in
remission and refractory groups can be subtle when each biomarker is considered individually. In this
work we aim to model the markers simultaneously and to use the model for discrimination between
groups.
1.2 Dynamic Longitudinal Discriminant Analysis
The SANAD data have been primarily analyzed elsewhere,1–4 with most previous work concentrated
on modelling of time to seizures using the baseline characteristics as prognostic factors3. A different
problem will be tackled in this paper. For each patient in our dataset, we have information on not only
their baseline characteristics and values of the longitudinal biomarkers but also on whether they belong
to the refractory or to the remission group. It is our aim to use these data to develop a statistical approach
which can be used to predict the five-year seizure status (i.e., pertinence into either the refractory or
the remission group) of a new patient based on their baseline characteristics as well as longitudinally
gathered biomarkers. As such the problem can be classified as a problem of longitudinal discriminant
analysis (LoDA).
In addition, we aim to refine the prediction of the seizure status whenever new longitudinal
observations become available at each consecutive visit. To predict the patient’s seizure status at
a particular time point we can use not only the last available longitudinal measurements (as is often
the case in clinical practice) but the whole longitudinal history of relevant biomarkers known by the time
we are conducting the prediction. Due to this dynamic update of the seizure status prediction, we will
refer to dynamic LoDA.
To formalize our research problem, let us assume that patients are to be classified into G > 1
prognostic groups (G = 2 in the SANAD application where the prognostic groups are the refractory
and the remission group). Let the group to which a patient belongs be represented by a value of the
random variable U ∈ {0, . . . , G− 1} which is only observable at time T > 0. Further, suppose that
information on the group membership can be predicted from R ≥ 1 longitudinally gathered markers
(R = 3 for the SANAD application). Let Yr =
(
Yr,1, . . . , Yr,nr
)
denote a random vector representing
the full longitudinal history of the rth marker (r = 1, . . . , R) being observed on a particular patient
at time points tr =
(
tr,1, . . . , tr,nr
)
, tr,1 < · · · < tr,nr < T . Note that we do not require equal time
sequences t1, . . . , tR for different markers, reflecting a common clinical scenario where not necessarily
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all markers are examined at all visits and allowing for a situation where each marker has its own visit
scheme. Furthermore, let vr,1, . . . , vr,nr ∈ Rpr be vectors of additional baseline as well as possibly
time-dependent covariates that may explain evolution of the longitudinal markers Yr,1, . . . , Yr,nr and
possibly contribute to discrimination. Let
C =
{
t1, . . . , tR, v1,1, . . . , vR,nR
}
denote complete information on the visit times and other covariates. For the SANAD application, apart
from time, baseline covariates will be considered and will include those mentioned in Section 1.1.
For given t (0 < t < T ), let Yr(t) be a subvector of Yr covering the measurements Yr,j with tr,j ≤ t
(j = 1, . . . , nr), i.e., longitudinal measurements of the rth marker by time t. Analogously, let C(t) denote
the covariate information by time t and finally, let Y(t) =
(
Y1(t), . . . , YR(t)
)
be a random vector
covering the observed values of all considered markers by time t.
A task of the dynamic LoDA is to use, at a given time point t (mostly corresponding to the visit time of
a particular patient), the longitudinal history Y(t) along with the covariate information, C(t), both known
by time t, to predict the value of the group allocation variable U , i.e., to predict the future prognosis of
a patient by allocating them into one of G prognostic groups. To develop a classification procedure, it is
assumed that a training (historical) dataset (the SANAD dataset in our case) is available where both the
group allocations and the longitudinal measurements along with the covariate values are available.
In order to avoid misunderstanding, we point out that a similar term dynamic prediction is nowadays
used for a problem which received considerable attention in recent years but is different from that of
ours. Namely, dynamic prediction is nowadays most often referred to in the context of time-to-event
analysis where it refers to estimation of a patient-specific survival distribution given their baseline and
longitudinal characteristics. This estimation is then repeated in time (dynamically) as new longitudinal
information becomes available. Classical methods in this context include landmarking (see the overview
by van Houwelingen and Putter5) and usage of methods of joint modelling of longitudinal and time-to-
event data6–9.
In contrast to those methods, we do not deal with dynamic estimation of a subject-specific time-to-
event distribution. We consider dynamic discriminant analysis where we aim to use historical data to
predict dynamically (also as new longitudinal information becomes available) the group membership of
a patient which is only known in the future.
Finally, note that most of the longitudinal biomarkers in the SANAD data (and many other
clinical applications) are either binary or counts, in which case existing methodology for longitudinal
discriminant analysis is scarce and largely unsuitable as will be indicated below.
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1.3 Longitudinal discriminant analysis based on mixed models
Classical methods of discriminant analysis, see, e.g., Chapter 4 of Hastie, Tibshirani and Friedman10
like linear discriminant analysis or discrimination based on logistic regression do not apply in our
context. These methods are often applied when only baseline characteristics or other cross-sectional
characteristics related to a chosen time point, common for all patients, are to be used for discrimination.
In more recent years relevant work has been done in capturing the longitudinal nature of clinical data
and using it for classification via methods of Longitudinal Discriminant Analysis.11–18 These authors
base their LoDA methodologies on the classical linear mixed model19 and propose discriminant methods
based on longitudinal measurements of a single (R = 1) continuous marker.
Nevertheless, using a single marker may be insufficient to accurately classify the subjects into
prognostic groups. By using multiple markers (R > 1), we may be able to more accurately classify
individuals using their longitudinal information. However, fewer developments have been made in the use
of multiple longitudinal markers for discrimination. We can mention Marshall et al.20 who use several
continuous markers and a multivariate non-linear mixed model to discriminate between women with
and without pregnancy abnormalities. Koma´rek et al.21 use three continuous markers and a multivariate
linear mixed model to evaluate a prognosis of primary biliary cirrhosis patients. In a similar way, Morrell
et al.22 use three continuous markers to predict the presence of prostate cancer.
As indicated above, most methods of LoDA exploit mixed model methodology. A benefit of its usage is
that data do not have to be measured at regular intervals. It is possible for patients to be observed different
numbers of times and at irregularly spaced intervals. In addition, it is not necessary for all biomarkers to
be measured on each patient at each visit. For example, it is possible for one biomarker to be measured
at one visit and then another at a different visit. This flexibility is useful in clinical applications where
regularly spaced observations are rarely achieved, and not all biomarkers are measured at the same time
point.
Unfortunately, the above referenced methodologies are not directly suitable when there are markers
that are not all continuous (as in our application). A related development made towards LoDA with
multiple markers of various types has been made by Fieuws et al.23 who predict renal graft failure
using combination of linear, non-linear and generalized linear mixed models. All considered markers
are combined into a multivariate mixed model by specifying a joint distribution for the random effects.
Computational complexity of the maximum likelihood estimation (MLE) is tackled by using a so called
pairwise fitting approach which proved to be a useful approximation towards MLE. They also show that
the prediction is better when considering multiple markers than by considering only a single marker.
In LoDA methods based on multivariate longitudinal markers, the complex correlation structure
between various markers is mostly taken into account by assuming a joint distribution for all random
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effects in the underlying mixed models. In each of the references mentioned previously, except for
Koma´rek et al.21, the random effects are assumed to follow a normal distribution. However, as shown by
Verbeke and Lesaffre,24 this assumption cannot easily be checked. Moreover, under misspecification of
the random effects distribution, estimates of the mixed model parameters may become seriously biased25
and consequently, the performance of the discriminant procedure may also be affected. In the mixed
models literature, several extensions avoiding the normality assumption for the random effects have been
proposed.26 Nevertheless, applications of such models in the LoDA context are still rare. One of the few
works in this direction is described by Koma´rek et al.21 who consider a multivariate linear mixed model
with distribution of random effects specified as a finite normal mixture, which robustifies the model
towards misspecification of the random effects distribution. To overcome the computational complexity
of the maximum likelihood estimation, they use Markov Chain Monte Carlo (MCMC) methodology
within a Bayesian framework.
1.4 Towards robust LoDA based on multivariate longitudinal markers of different
types
The aim of this paper is to extend a multivariate LoDA method so that (i) it allows for multiple
longitudinal markers of different types as requested by data from the SANAD study and (ii) the
underlying model is robustified against possible misspecification of the random effects distribution.
We are aware of two methodologies available in the literature that satisfy either (i) or (ii) but none of
them both of the requirements. The approach of Koma´rek et al.21 fulfills (ii) but only continuous markers
can be used. We allow for binary and count biomarkers by replacing the underlying multivariate linear
mixed model with the multivariate generalized linear mixed model (MGLMM).
On the other hand, the method of Fieuws et al.23 allows for markers of different nature but normality
of the random effects is assumed. By using a pairwise fitting approach, these authors attempt to overcome
the complexity of finding the maximum likelihood parameter estimates. In this paper we take a different
approach by using Bayesian methods with MCMC estimation and considering a normal mixture in the
distribution of random effects to robustify the model against misspecification of the random effects
distribution.
Conceptually, the LoDA methodology proposed here follows that of Koma´rek et al.21. Nevertheless,
to allow also for binary and count biomarkers, we replace the underlying multivariate linear mixed model
used therein by the multivariate generalized linear mixed model (MGLMM). To robustify the model
against misspecification of the random effects distribution, we shall consider a normal mixture in the
distribution of random effects. In this paper, we obtain a robust group-specific model that will be further
used in the LoDA procedure.
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An outline of the remainder of the paper is as follows. In Section 2 we describe the MGLMM with
a mixture distribution for the random effects. This allows us to jointly model the longitudinal profile of
each marker in each prognostic group. We also describe the MCMC procedure that is applied to infer
on the model parameters. Section 3 describes the longitudinal discriminant analysis used to classify new
patients into prognostic groups. An example of our methodology applied to the SANAD data is shown in
Section 4 with a summary provided in Section 5.
2 Multivariate generalized linear mixed models with a normal mixture in the
random effects distribution
2.1 Model
The basis for the LoDA procedure, explained further in Section 3, is a multivariate generalized linear
mixed model (MGLMM) with a normal mixture in the random effects distribution. This is assumed for
the longitudinal evolution of considered markers in each prognostic group. Specifically, given U = g
(the group g, to which a patient belongs), g = 0, . . . , G− 1, we assume for observations of marker r:
Yr (r = 1, . . . , R), obtained at time points tr with covariate vectors (corresponding to potentially fixed
effects, x, or random effects z) vr,1, . . . , vr,nr a generalized linear mixed model (GLMM). To this
end, it is assumed that a particular subject is characterized by values of a latent random effects vector
b =
(
b1, . . . , bR
)
and the jth longitudinal observation (j = 1, . . . , nr) of the rth marker is assumed
to follow, given U = g and given b, a distribution from an exponential family (e.g., normal, Poisson,
Bernoulli) with a dispersion parameter φgr and the expectation given as
h−1r
{
E
(
Yr,j
∣∣b, U = g)} = xg⊤r,jαgr + zg⊤r,jbr, r = 1, . . . , R, j = 1, . . . , nr. (1)
In (1), h−1r is a known link function used in the GLMM for the rth marker (e.g., logit for Bernoulli
responses, log for Poisson variables), xgr,j = xgr,j(C) and zgr,j = zgr,j(C) are covariate vectors used in
a model for the prognostic group g derived from the information on the visit times and the covariates C.
Note that different covariate sets x and z can be used in models for different prognostic groups. Further,
αgr are unknown parameters (fixed effects) related to the model for the rth marker in the group g. As
a standard feature of the exponential family, the dispersion parameter φgr is either known (e.g., being
equal to 1 for Bernoulli or Poisson responses) or unknown (e.g., residual variance in a GLMM with
Gaussian response).
In our SANAD example, we consider R = 3 longitudinal biomarkers, Y1 denote a vector of binary
variables that represent whether or not the patient experienced seizures since the last clinic visit, Y2
denote a vector holding the total numbers of seizures since the last clinic visit under the transformation
Prepared using sagej.cls
10 Journal Title XX(X)
log(1 + total seizures) and the vector Y3 records the numbers of adverse events experienced since the
previous clinic visit. Each biomarker is modelled in each group using the same set of six covariates, i.e.,
x
g
r,j =
(
xj,1, . . . , xj,6
)⊤
, where xj,1, . . . , xj,6 corresponds to (1) time since last visit, (2) time since
diagnosis, (3) age at diagnosis, (4) epilepsy type, (5) sex, (6) randomisation period. With respect to the
random effects structure, model of each marker in each group contains a random intercept. This means
z
g
r,j = 1 and three-dimensional random effects vector b =
(
b1, b2, b3
)⊤ (random intercepts for the three
markers) is involved. More details on the model parameters and biomarkers are given in Section 4.
Possible correlation between repeated observations of both the same marker and different markers
measured on the same patient is accounted for by inclusion of the random effect vector b. Given its value,
all single longitudinal measurements Y1,1, . . . , YR,nR are assumed to be independent. Traditionally it is
assumed that the random effect vector b follows a normal distribution. Nevertheless, as pointed out in
the introduction, this assumption is difficult to assess and may have a crucial impact on the validity of the
statistical inference we aim to conduct using the proposed model. A suitable flexible model robustified
towards misspecification of the random effects distribution consists of assuming a normal mixture for the
random effects. For our model towards LoDA, possibly different normal mixtures should be considered
in different prognostic groups. Hence, formally, we assume
b
∣∣U = g ∼ Kg∑
k=1
w
g
kMVN
(
µ
g
k, D
g
k
)
, (2)
where MVN (µ, D) stands for a multivariate normal distribution with the mean vector µ and
a covariance matrix D. Unknown parameters of the mixture model (2) in the prognostic group g are:
the mixture weights wg =
(
w
g
1 , . . . , w
g
Kg
) (0 < wgk < 1, k = 1, . . . ,Kg, ∑Kgk=1 wgk = 1), the mixture
means µ
g
1, . . . , µ
g
Kg and the mixture covariance matrices D
g
1, . . . , D
g
Kg . The number of mixture
components,Kg is initially assumed to be known. We return to its choice later in Section 4.2.
As mentioned above, a primary purpose of usage of the mixture in (2) is to robustify our model against
misspecification of the random effects distribution. At this place, we should mention that also in other
contexts, mixtures proved to provide a flexible distributional model26–28 and hence can be considered as
a sort of robustification against violation of the assumption on the random effects distribution.
In the following, let ψg denote a vector of unknown parameters of the GLMM model (1) in group
g. That is, ψg consists of the fixed effects αg1, . . . , α
g
R and a subset of the dispersion parameters
φ
g
1, . . . , φ
g
R that are not constant for given exponential family distribution. Analogously, let θ
g denote
a vector of unknown parameters of the mixture model (2) in the distribution of random effects in
group g. That is, θg consists of the mixture weights wg , the mixture means µg1, . . . , µ
g
Kg and the
mixture covariance matrices Dg1, . . . , D
g
Kg . For observed values y1 =
(
y1,1, . . . , y1,n1
)
, . . ., yR =
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(
yR,1, . . . , yR,nR
)
of the longitudinal markers Y =
(
Y1, . . . , YR
)
for a subject from the prognostic
group g, an implied (marginal) density fmargg (·; ψg, θg, C) is
fmargg
(
y1, . . . , yR; ψ
g, θg, C
)
=
∫
f condg
(
y1, . . . , yR
∣∣b; ψg, C) f ranefg (b; θg) db, (3)
where f condg (·;
∣∣b; ψg, θg) denotes a (conditional) density of the observed markers given the random
effect vectors and finally, f ranefg (·; θg) is a density of the random effects. For the multivariate GLMM
with a normal mixture in the random effects distribution, we have
f condg
(
y1, . . . , yR
∣∣b; ψg, C) = R∏
r=1
nr∏
j=1
pr
(
yr,j
∣∣b; ψg, C), (4)
f ranefg
(
b; θg
)
=
Kg∑
k=1
w
g
k ϕ(b; µ
g
k, D
g
k), (5)
where pr
(
·
∣∣b; ψg, C) is a density of the exponential family distribution assumed for the rth marker,
r = 1, . . . , R, whose expectation depends on the random effects vector b, the fixed effectsαgr (subvector
of the parameter vector ψg) and on the covariate information C by the GLMM model (1). Further,
ϕ(·; µ, D) denotes a density of the multivariate normal distribution with mean µ and a covariance
matrix D.
2.2 Sampling based Bayesian inference
For a training dataset of size N , composed of observed values yi,1 =
(
yi,1,1, . . . , yi,1,ni,1
)
, . . ., yi,R =(
yi,R,1, . . . , yi,R,ni,R
)
of the longitudinal markers Yi =
(
Yi,1, . . . , Yi,R
)
, component allocations
Ui = ui, the visit times ti,r =
(
ti,r,1, . . . , ti,r,ni,r
)
and the covariate vectors vi,r,j , i = 1, . . . , N , r =
1, . . . , R, j = 1, . . . , ni,r, a likelihood basing the inference on the model parameters for a prognostic
group g ∈ {0, . . . , G− 1} is (while assuming independence between the study subjects)
Lg(ψ
g, θg) =
∏
i: ui=g
fmargg
(
yi,1, . . . , yi,R; ψ
g, θg, Ci
)
=
∏
i: ui=g
∫
f condg
(
yi,1, . . . , yi,R
∣∣bi; ψg, Ci) f ranefg (bi; θg) dbi
=
∏
i: ui=g
∫
R∏
r=1
ni,r∏
j=1
pr
(
yi,r,j
∣∣bi; ψg, Ci){Kg∑
k=1
w
g
k ϕ
(
bi; µ
g
k, D
g
k
)}
dbi, (6)
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where Ci =
{
ti,1, . . . , ti,R, vi,1,1, . . . , vi,R,ni,R
}
, i = 1, . . . , N . Note that (6) could also be written as
Lg(ψ
g, θg) =
∏
i: ui=g
{ Kg∑
k=1
w
g
k
∫
R∏
r=1
ni,r∏
j=1
pr
(
yi,r,j
∣∣bi; ψg, Ci)ϕ(bi; µgk, Dgk)dbi
}
and hence the MGLMM with a normal mixture in the random effects distribution that we use to model
a longitudinal evolution of the markers in each of the prognostic groups, can also be interpreted as
a mixture of the MGLMM’s with a normal distribution of random effects. This allowed Koma´rek and
Koma´rkova´29 to use the model for clustering (i.e., unsupervised classification) based on longitudinal
data. Use of their clustering methodology in our context would mean (unsupervised) division of subjects
of a given gth prognostic group into additional smaller subgroups which is not the aim of this paper.
Nevertheless, we can exploit a methodology developed in Koma´rek and Koma´rkova´29 for estimation of
unknown parametersψg and θg for each prognostic group g ∈ {0, . . . , G− 1}.
Due to a mixture nature of the likelihood (6) which additionally involves analytically intractable
integration where the integrand combines a general exponential family and a normal density, maximum-
likelihood based inference is tractable only with difficulties. For this reason a Markov chain Monte Carlo
(MCMC) based Bayesian estimation as proposed by Koma´rek and Koma´rkova´29 will be adopted here.
In the following, let p be a generic symbol for a density. Bayesian inference in the prognostic group
g ∈ {0, . . . , G− 1} consists of specifying a prior distribution p
(
ψg, θg
)
for the model parameters and
then basing the inference on the posterior distribution p
(
ψg, θg | Yg
)
, where Yg =
{
Yi : ui = g
}
⊂
Y =
{
Yi : i = 1, . . . , N
}
represent observed longitudinal markers in group g. Using Bayes theorem,
the posterior distribution combines the prior distribution and the likelihood (6) as
p
(
ψg, θg | Yg
)
∝ Lg(ψ
g, θg) p
(
ψg, θg
)
. (7)
Koma´rek and Koma´rkova´29 describe (i) how to specify the prior distribution p(ψg, θg) in a weakly
informative way if no prior information on the model parameters is available, (ii) how to use the MCMC
methodology to obtain a sample
Sg =
{(
ψ
g,(m), θg,(m)
)
: m = 1, . . . ,M
}
,
ψg,(m) =
(
α
g,(m)
1 , . . . , α
g,(m)
R , φ
g,(m)
1 , . . . , φ
g,(m)
R
)
,
θg,(m) =
(
w
g,(m)
1 , . . . , w
g,(m)
Kg , µ
g,(m)
1 , . . . , µ
g,(m)
Kg , D
g,(m)
1 , . . . , D
g,(m)
Kg
)
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of size M from the posterior distribution (7), (iii) how to infer on a number of mixture components
Kg in a mixture distribution (5) assumed for random effects. We refer therein for details. Moreover,
an implementation of the MCMC methodology is available as a contributed package mixAK30 of the R
software31.
Finally, if it is assumed that the model parameters for different prognostic groups are apriori
independent and a joint prior distribution for model parameters ψ = (ψ0, . . . , ψG−1), θ =(
θ
0, . . . , θG−1
)
from all prognostic groups takes a product form p(ψ, θ) =
∏G−1
g=0 p
(
ψ
g, θg
)
.
A sample S =
{
S0, . . . , SG−1
}
obtained by combining G independently obtained samples
S0, . . . , SG−1, is then also a sample from the joint posterior distribution p(ψ, θ | Y) of the model
parameters for all prognostic groups given the full training dataset Y . This follows from a classical
assumption of independence between the study subjects which gives a product form of the likelihood of
the full training dataset beingL(ψ, θ) =
∏G−1
g=0 Lg
(
ψg, θg
)
leading to the product form of the posterior
distribution
p(ψ, θ | Y) =
G−1∏
g=0
p
(
ψg, θg
∣∣Yg). (8)
3 Longitudinal discriminant analysis procedure
Let Ynew =
(
Ynew,1, . . . , Ynew,R
)
denote a random vector that represents observed values
ynew,1, . . . , ynew,R of the longitudinal markers for a new subject (in general known by some time t < T
but we suppress this in notation for clarity) that is to be classified into one of the G prognostic groups and
let Cnew =
{
tnew,1, . . . , tnew,R, vnew,1,1, . . . , vnew,R,nnew,R
}
be the corresponding visit times and
other covariate values (again, possibly known by some time t < T ). Further, let Unew ∈ {0, . . . , G− 1}
be a random variable that represents allocation of the new subject into one of the G groups. At this
point, we assume that a value unew of Unew is not observed and it is our aim to predict it using
the LoDA procedure based on the training dataset. Before we do so, additional notation is needed.
Let pig = P(Unew = g), g = 0, . . . , G− 1, denote prevalences of the prognostic groups in the study
population (0 < pig < 1, g = 0, . . . , G− 1,
∑G−1
g=0 pig = 1) which, as is common in applications of the
discriminant analysis, are assumed to be known in advance and are often called in this context prior
group probabilities.
3.1 Full Bayesian prediction
Having proposed the Bayesian inference for the model parameters using the training dataset Y , the
problem of classification of a new subject in a full Bayesian setting coincides with a problem of estimating
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posterior probabilities
Pmargnew,g = P
(
Unew = g
∣∣Ynew, Y), g = 0, . . . , G− 1.
Here, Ynew denotes the longitudinal information for a new patient. Specifically, in the context of the
SANAD study, it denotes all the longitudinal information available for a patient up until the time at
which a prediction is to be made. It then follows from decision theory for classification10 that if costs of
all types of misclassification are the same, the new subject is classified into that group for whichPmargnew,g is
maximal. That is, Ûnew = ûnew, such thatPmargnew,ûnew = maxg=0,...,G−1P
marg
new,g. Different strategies can,
however, be adopted on how to exploit the posterior group allocation probabilities towards classification
depending on a clinical importance of different types of misclassification, see Section 4.1 for illustration.
To calculate Pmargnew,g, we first note that
Pmargnew,g =
∫
P
(
Unew = g,
∣∣Ynew , ψ, θ, Y) p(ψ, θ | Y) d(ψ, θ) (9)
= Ep(ψ, θ | Y) P
(
Unew = g,
∣∣Ynew, ψ, θ, Y), g = 0, . . . , G− 1,
where Ep(ψ, θ | Y) denotes expectation with respect to the posterior distribution (8) of the model
parameters given the training dataset. If it is further assumed, as is common in this setting, that given
the knowledge of the model parameters, a training dataset Y does not bear any additional information
concerning the new subject, we obtain (for g = 0, . . . , G− 1)
P
(
Unew = g
∣∣Ynew, ψ, θ, Y) = P(Unew = g ∣∣Ynew , ψ, θ) =: Pmargnew,g(ψ, θ), (10)
where another use of Bayes theorem provides
Pmargnew,g(ψ, θ) =
pig f
marg
g
(
ynew,1, . . . , ynew,R; ψ
g, θg, Cnew
)∑G−1
g˜=0 pig˜ f
marg
g˜
(
ynew,1, . . . , ynew,R; ψ
g˜, θg˜, Cnew
) .
With the frequentist (non-Bayesian) LoDA methodologies,32;33 classification of the new subjects is
usually based on the group probabilities (10), in which the unknown parameters ψg, θg, g = 1, . . . , G,
are replaced by their suitable estimates, e.g., maximum-likelihood estimates. On the other hand, the full
Bayesian approach dictates to use the posterior probabilities Pmargnew,g (9), which are the posterior means
(over the posterior distribution of the unknown parameters) of the group probabilitiesPmargnew,g(ψ, θ) (10).
Having used the MCMC inference, the values of Pmargnew,g are approximated using the generated samples
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S0, . . . , SG−1 as
P̂margnew,g =
1
M
M∑
m=1
Pmargnew,g
(
ψ(m), θ(m)
)
, g = 0, . . . , G− 1. (11)
Finally, we note that when evaluating (11), analytically intractable integral from (3) is in general
involved in calculation of the marginal densities fmargg (g = 0, . . . , G− 1). Koma´rek and Koma´rkova´29
use a Laplace approximation to this end and we will exploit it here as well.
3.2 Marginal, conditional and random effects prediction
In several previous works on LoDA based on the mixed models21;32;33, the authors distinguish so called
marginal, conditional and random effects prediction, each having its own pros and cons and more
importantly, providing prediction of different quality depending on problem at hand. Hence, in any
application of the LoDA based on the mixed model, it is useful to consider all these types and then
to choose that one providing the best classification results.
The marginal prediction in the original terminology of Morrell et al32 corresponds, in fact, to
using the group probabilities (10) as a basis for classification of the new subject, which next to
the model parameters depend only on the values of the (observable) longitudinal markers Ynew =(
ynew,1, . . . , ynew,R
)
of the new subject. On the other hand, for both the conditional and the random
effects prediction, it is necessary to represent the new object also by the values of the (unobservable)
random effect vector bnew for which the assumed joint distribution, given the group allocation, follows
from the assumed models (4) and (5). That is, the joint distribution of Ynew , bnew given Unew = g has,
for g = 0, . . . , G− 1, a density
f jointg
(
ynew,1, . . . , ynew,R, bnew
∣∣ψg, θg, Cnew)
= f condg
(
ynew,1, . . . , ynew,R
∣∣bnew ; ψg, Cnew) f ranefg (bnew; θg), (12)
where f condg and f ranefg , are given by (4) and (5), respectively.
To calculate the random effects prediction, the group probabilities (10) are, for g = 0, . . . , G− 1,
replaced by
Pranefnew,g (b
0
new, . . . , b
G−1
new , ψ, θ) :=
pig f
ranef
g
(
bgnew; θ
g
)∑G−1
g˜=0 pig˜ f
ranef
g˜
(
b
g˜
new; θ
g˜
) ,
where bgnew, g = 0, . . . , G− 1, is a suitable characteristic of the (predictive) distribution of bnew given
Unew = g, given the observed value of the longitudinal markers Ynew =
(
ynew,1, . . . , ynew,R
)
and
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given the model parameters ψg and θg from the model in group g. This predictive distribution follows
directly from the joint distribution (12):
p
(
bnew
∣∣Unew = g, ynew,1, . . . , ynew,R, ψg, θg)
∝ f jointg
(
ynew,1, . . . , ynew,R, bnew
∣∣ψg, θg, Cnew). (13)
The mean of this distribution, which is, in fact, the empirical Bayes estimator of the random effect value
given the group, is usually exploited in the LoDA procedure33. With the Bayesian approach, it is natural
to consider, in the mood of the Bayesian data augmentation34, the unobservable random effect value
bnew as additional model parameter with the prior distribution (conditioned by the allocation in group g)
given by (4). For classification, the MCMC based estimators
P̂ranefnew,g =
1
M
M∑
m=1
Pranefnew,g
(
b0,(m)new , . . . , b
G−1,(m)
new , ψ
(m), θ(m)
)
, g = 0, . . . , G− 1,
are used, where bg,(m)new , g = 0, . . . , G− 1, m = 1, . . . , M , is sampled from the predictive distribution
(13) with ψg = ψg,(m) and θg = θg,(m), m = 1, . . . ,M .
In a similar way, the conditional prediction is obtained. It first replaces the group probabilities (10) by
(g = 0, . . . , G− 1)
Pcondnew,g(b
0
new , . . . , b
G−1
new , ψ, θ) :=
pig f
cond
g
(
ynew,1, . . . , ynew,R
∣∣bgnew; ψg)∑G−1
g˜=0 pig˜ f
cond
g˜
(
ynew,1, . . . , ynew,R
∣∣bg˜new ; ψg˜) .
With the MCMC based Bayesian inference, the estimators
P̂condnew,g =
1
M
M∑
m=1
Pcondnew,g
(
b0,(m)new , . . . , b
G−1,(m)
new , ψ
(m), θ(m)
)
, g = 0, . . . , G− 1,
of the group probabilities are used for classification.
We have described here three possible methods of prediction. It is entirely possible that different
choices of method would result in different predicted group status for a particular patient. In the process
of testing and building the model one must assess the predictive ability of any of the three methods to
determine which works best.
Prepared using sagej.cls
Hughes et al. 17
4 Application to SANAD data
Section 1 gives an overview of the SANAD data and summary information. In this section we present the
results of the methodology presented in Sections 2 and 3 when applied to the SANAD data.
As described in Section 1, we consider three longitudinal markers to predict refractory or remission
patients. For the binary marker, whether a patient had seizures or not since their last visit, we use a logistic
model as the form of the GLMM. For the number of adverse events (count marker) we consider a log-
Poisson model. Finally, for the number of seizures experienced since the previous visit, we utilize a log
transformation of the form, log(1 + total seizures) and select a Gaussian model. These models are
combined through the inclusion of jointly distributed random effects to induce correlation. We allow each
longitudinal marker to have a random intercept and allow these three random intercepts to be correlated.
As explanatory fixed effect covariates we will use (in both prognostic groups) (1) time since last visit
(TLFU) in order to account for the fact the visit schedule is irregular and hence the biomarkers are
not collected over a fixed time period, (2) time since diagnosis (TDiag), (3) age at t = 0 (Age), (4)
epilepsy type (Type), a binary indicator as to whether the patient has generalized epilepsy or not, (5)
sex (Sex), and (6) a binary covariate indicating whether or not recruitment occurred before the 6th June
2001 (RecP). The reason for this final covariate is that a new drug was added to the trial on this date
which may have introduced differences among patients in the longitudinal profiles. In the remission and
the refractory prognostic group there are 57.6% and 53.6% of males, respectively. The median (min,
lower-quartile, upper-quartile, max) age at t = 0 in the two groups is 30 (5, 17, 47, 86) and 32 (5, 20, 42,
71), respectively. In total, 23.7% of patients in the remission group had generalized epilepsy, compared
to 14% of patients in the refractory group. In the example presented here, we consider for simplicity the
case where the number of mixture components in the random effects distribution (2) is the same for each
prognostic group (K0 = K1 = K) although this is not a necessary requirement of our methodology.
4.1 Dynamic LoDA procedure
As indicated in Section 1.2, we update the probabilities of a future patient’s group membership each time
new information is available. This is achieved by applying repeatedly the formulas of Section 3 while
taking information available by each visit time in place of Ynew and Cnew. In order to then use these
probabilities to allocate the patient into either the refractory or remission group we propose a dynamic
discriminant analysis allocation scheme, following closely the procedure described in Brant et al.12;22.
In our application, primary interest lies in early and correct diagnosis of refractory patients. With our
dynamic LoDA procedure, we decide at each visit whether a patient can be ultimately classified as
refractory or whether it is necessary to continue with their follow-up before final classification can be
deduced.
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We proceed as follows. We consider the first clinic visit for each patient. If the estimated probability of
being in the refractory group is greater than a chosen cutoff, c, then we assign this patient to the refractory
group and stop predicting for this patient. If the probability is lower than c, then we proceed to the next
visit and the patient remains under observation, repeating the process until either the patient has been
classed as refractory or all their visits have been used. Any patient not predicted as refractory remains
under observation until the last visit before their status is confirmed (either by achieving remission or
by the five years since diagnosis ending). Any patient not predicted as refractory by this final visit is
predicted as remission.
Of course, other schemes would have been possible. If it was the case that we were equally interested
in both remission and refractory patients we could assign a patient to either group if their probability of
belonging to the group was greater than c, and only continue observing if neither probability was greater
than c.
For either scheme, the cutoff c must be chosen by the investigator. Many methods exist to do this,
depending on the needs of the investigation. We remark that with our proposed scheme, even if we
classify patients into the two groups dynamically in time, only one decision concerning the group
membership is taken for each patient. Consequently, classical methods of evaluation of the predictive
accuracy of a binary classifier like those based on the Receiver Operating Characteristic (ROC) curve can
be considered. In this paper, we select the cutoff linked to the top left most point on the ROC curve. Other
alternatives, such as the Youden index, or specifying a desired sensitivity, specificity or probability of
correct classification (PCC) could also be chosen. In the model building and testing stage of an analysis,
a range of cutoff values can be tested and predictive accuracy compared. Following this procedure, the
best cut-off can be selected and used for future classification of new patients.
In the following analysis, we use 70% of our data to train the models and the remaining 30% to test
the predictive accuracy. We repeat this process 100 times in a cross-validation procedure. For each split
of the data into training and test sets, we calculate various measures of predictive accuracy and average
them across the 100 splits.
4.2 Selecting the number of components in the mixture distribution
The multivariate generalized linear mixed model introduced in Section 2 which forms the basis of the
discrimination procedure considers a normal mixture (2) in the random effects distribution. In general,
the number of mixture components for each of the prognostic groups, K0 and K1, must be estimated
from the training dataset. Koma´rek and Koma´rkova´29 suggest to use the penalized expected deviance
(PED35) to this end and we can, in principle, use this approach as well, separately for models in each
prognostic group.
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Table 1. Penalized Expected Deviance for models with K = 1, 2, 3, 4 mixture components in the random
effects distribution. These values were based upon the full data available in each group. The models with the
best PED values are shown in bold for each group.
Group K = 1 K = 2 K = 3 K = 4
Remission 37 305 36 669 36 578 36 607
Refractory 9 734 9 740 10 403 10 497
Table 2. Comparison of the choice of K and its effect on the marginal prediction accuracy. The predictions are
based on 100 splits of the data where 70% of the patients in each group were used to train the MGLMMs and
the remaining 30% were used to test the predictive accuracy.
Cutoff Sensitivity Specificity PCC AUC PPV NPV
K = 1 0.75 0.94 0.91 0.91 0.96 0.55 0.99
K = 2 0.74 0.94 0.92 0.92 0.97 0.58 0.99
K = 3 0.67 0.93 0.91 0.91 0.96 0.56 0.99
K = 4 0.71 0.93 0.91 0.91 0.96 0.55 0.99
Table 1, which shows the PED values (lower value means a better model) for models with different
values of K in the two groups, suggests to use K = 1 in the refractory group (although improvement on
K = 2 is minimal). In the remission group, K = 3 seems to provide the best model, nevertheless, the
PED improvement compared to K = 2 is relatively small. Note that the PED values were explored using
the full data in each group before any splits of the data into training and test groups.
Nevertheless, since our primary interest lies in the prediction of the patient’s status (at a pre-specified
future time point), it is more natural in our context, to evaluate the models and to select an optimal
value of K for the random effects distribution in (2) in each group by comparing the predictive ability
of each of the models using our dynamic LoDA scheme. This has been done here using the cross-
validation procedure where we split the data into training and test sets 100 times and averaged the
results. For simplicity, we have assumed the same number of mixture components in both the remission
and refractory groups, i.e., K0 = K1 = K . For the sake of space we just present here the results when
using the marginal prediction method since this was the method that most consistently gave the best
classification results, although the results for the conditional predictions were very similar. Table 2 shows
that there is a slight improvement in specificity, positive predictive value (PPV), probability of correct
classification (PCC) and area under curve (AUC) when using more than one component in the mixture
distribution, and particularly for K = 2. The other accuracy measures appear to be very similar across all
considered values of K , althoughK = 2 shows consistently the highest value (NPV= negative predictive
value). The cutoff values reported represent the choice of cutoff that gave the point on the ROC curves
closest to the top left corner for each choice of K . The combined results from Tables 1 and 2 show that
there is a benefit in using K > 1 mixture components in terms of PED for the remission group (with
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negligible loss in the refractory group), and that the classification when using these models is the same
as, or slightly better than when using models with K = 1.
4.3 Results of the dynamic LoDA
Having shown that there is an advantage to selecting K > 1 components in the distribution of the random
effects we use K = 2 since this gives the best classification accuracy.
A summary of the model parameter estimates is given in Table 3. The model parameters, in both the
seizures and the number of seizures models, for time since recruitment switch signs between groups,
which indicates that the probability of experiencing seizures, and of the number of seizures experienced
increases with time in the refractory group, whilst in the remission group this probability decreases.
Similarly, the expected value of the random intercept for the seizures is −0.32 in the remission group
and 1.25 in the refractory group. This is due to the fact that the average probability of having seizures
soon after recruitment is below 0.5 in the remission group, but above 0.5 in the refractory group, which
is supported by the profile plots in Figure 1.
By comparing the parameter estimates in Table 3, we can see that for patients who will ultimately
achieve remission, older patients, male patients, and patients without generalized epilepsy are less likely
to have seizures and expected to have fewer seizures than young patients, female patients and patients
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Figure 2. Receiver Operating Characteristic curves of the dynamic LoDA using the marginal (solid red),
conditional (dashed blue) and random effects (dot dashed green) prediction methods.
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Table 3. Posterior summary statistics and highest posterior density (HPD) credible intervals for the fixed
effects, and random effects in a model with K = 2. These statistics are based on the full longitudinal data
available in each group.
Remission Refractory
Posterior Mean 95% HPD Interval Posterior Mean 95% HPD Interval
Seizures (Y1)
TLFU (days) (α1,1) 1.2×10−4 (−7.2, 9.4)×10−4 1×10−2 (1, 1.4)×10−2
TDiag (days) (α1,2) −3.7×10−3 (−4.1, −3.3)×10−3 4.8×10−4 (4, 91)×10−5
Age (α1,3) −6.2×10−3 (−12, 0)×10−3 7.9×10−3 (−1.1, 2.6)×10−2
Type (α1,4) 0.64 (0.39, 0.87) 1.00 (0.30, 1.66)
Sex (α1,5) −0.10 (−0.31, 0.12) −0.09 (−0.69, 0.53)
RecP (α1,6) −0.47 (−0.69,−0.26) 1.44 (−0.71, 3.75)
E(Intercept) E(b1) −0.32 (−0.64,−0.01) 1.25 (−0.66, 3.83)
SD(Intercept) SD(b1) 2.11 (1.94, 2.28) 3.43 (1.14, 7.62)
log(1+ Number of Seizures) (Y2)
TLFU (days)(α2,1) 1.1×10−3 (9,14)×10−4 3×10−3 (2.6,3.7)×10−3
TDiag (days) (α2,2) −1.6×10−3 (−1.7, −1.5)×10−3 1.6×10−4 (3.8, 29)×10−5
Age (α2,3) −3.6×10−3 (−5.4, −2)×10−3 −5.6×10−3 (−17, 4.6)×10−3
Type (α2,4) 0.11 (0.03, 0.18) 0.37 (0.02, 0.77)
Sex (α2,5) −0.06 (−0.13, 0.01) −0.29 (−0.63, 0.04)
RecP (α2,6) −0.11 (−0.18,−0.04) 0.41 (−0.63, 1.36)
E(Intercept) E(b2) 1.05 (0.96, 1.15) 1.77 (1.34, 2.22)
SD(Intercept) SD(b2) 0.78 (0.74, 0.83) 1.05 (0.92, 1.20)
SD(error) φ2 0.89 (0.88, 0.91) 1.11 (1.07, 1.15)
Number of Adverse Events (Y3)
TLFU (days) (α3,1) −1.3×10−3 (−1.9, −1)×10−3 −1×10−3 (−1.6, 0)×10−3
TDiag (days) (α3,2) −1.2×10−3 (−1.4, −1)×10−3 −3.6×10−3 (−5.3, −1.9)×10−4
Age (α3,3) 7.1×10−3 (3.7, 10)×10−3 1.8×10−2 (1, 2.6)×10−2
Type (α3,4) 0.23 (0.09, 0.36) −0.16 (−0.48, 0.16)
Sex (α3,5) −0.09 (−0.22, 0.03) −0.16 (−0.42, 0.11)
RecP (α3,6) −0.28 (−0.40,−0.16) 0.63 (−0.26, 1.51)
E(Intcpt) E(b3) −0.90 (−1.08,−0.71) −0.92 (−1.32,−0.53)
SD(Intercept) SD(b3) 0.93 (0.84, 1.01) 0.76 (0.51, 1.16)
with generalized epilepsy respectively. Patients in both models are expected to experience fewer adverse
events as time from diagnosis increases, perhaps because the clinicians have had more time to find
suitable medication to avoid side effects in some patients.
The marginal and conditional dynamic LoDA approaches give good classification, as shown by high
sensitivity, specificity and PCC values (see Table 5, first two columns). The random effects prediction
approach works less well in this case. We are not the first to have noticed differences in the predictive
accuracy of the three approaches. Koma´rek et al.21 found that the random effects prediction was the best
when considering a study of primary biliary cirrhosis, whilst Morrell et al.33 found that the marginal
method was the most successful at identifying prostate cancer patients. Which dynamic LoDA method
works best seems to depend upon the application considered. The cutoff value regarded as optimal (e.g.
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Table 4. The longitudinal observations on a randomly selected refractory and remission patient. The refractory
patient was a 35 year old male with generalized epilepsy randomized before 6th June 2001, whilst the
remission patient was a 44 year old male with generalized epilepsy also randomized before 6th June 2001.
time P (refractory) seizures Total Number of Seizures Number of Adverse Events
Patient (a)
93 0.15 Yes 10 3
184 0.21 Yes 36 2
366 0.33 Yes 40 0
720 0.71 Yes 70 0
833 0.91 Yes 30 3
924 0.99 Yes 100 3
1101 1 Yes 150 0
1295 1 Yes 72 0
1480 1 Yes 100 0
Patient (b)
84 0.02 No 0 1
259 0.00 No 0 0
418 0.23 Yes 20 0
509 0.12 No 0 2
718 0.02 No 0 0
862 - No 0 2
0.74 for the marginal prediction in Table 5) corresponds to the point closest to the top left hand corner of
the ROC curve (see Figure 2). We point out here that the three methods of prediction are to be regarded
as alternative competing potential classifiers. As such there is no reason to expect that they give similar
performance. Each method has a different cutoff that is optimal for that method. This is to be expected,
and we note that these cutoffs are not directly comparable, since the probabilities they relate to are not
the same.
To illustrate our allocation scheme outlined in Section 4.1 and to help to interpret the parameter
estimates in context of discrimination, we present the longitudinal data of two patients in Table 4, one
patient who achieved remission and another who had refractory epilepsy. We present for each patient
the time of their clinic visits and their longitudinal information gathered at each visit. First consider the
refractory patient, Patient (a). At his first four appointments, although he has had many seizures and in
some cases experienced adverse events, his probability of being in the refractory group does not yet rise
above 0.74 (the cutoff determined to be optimal in Table 5). Up until this point he would not be predicted
as refractory and would remain under observation. Only at the fifth visit does this probability rise above
the cutoff of 0.74 and at this point the marginal prediction method allocates him to the refractory group.
For this particular patient this turned out to be the correct prediction as can be seen by viewing his further
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clinic visits. By considering his baseline characteristics with the estimated model parameters in Table 3
we see that patients with generalized epilepsy have increased likelihood of experiencing seizures (and
in fact many seizures) even if the patient would ultimately achieve remission. This is one reason why
Patient (a) initially has low probability of being in the refractory group despite experiencing seizures. At
these early time points, we are not yet sufficiently confident that we can predict he will be refractory.
However, we are still able to accurately classify him after 833 days (approx 2 years and 3 months) which
is considerably earlier than waiting five years to determine their status.
In contrast, Patient (b) ultimately achieves remission. He has initially low probabilities of being
refractory due to having no seizures. When he does experience seizures, his probability of being
refractory increases to 0.23 but is still well below the required cutoff of 0.74. As this patient experiences
no further seizures, his probability of being refractory drops again and at the visit prior to remission being
confirmed he is correctly classified as remission. This is confirmed to be correct at his visit when t = 862
days since it is observed that he has had at least 12 months without experiencing seizures.
The allocation scheme has been specifically designed to identify refractory patients. We have set up
a scheme whereby as soon as a patient is classified as refractory, we stop predicting for this patient and
investigate alternative treatment options. Questions may arise in these kind of settings as to how long
one must wait to be confident of the prediction. We have shown that by observing a patient until their
probability of being refractory is greater than 0.74 then over 90% of remission and refractory patients are
correctly identified.
A further significant finding in the example is the gain in lead time by using the dynamic approach.
We define the lead time as the average time, before clinical classification can be confirmed, at which our
method can correctly predict a patient as belonging to the refractory group. The corresponding prediction
time is the average time since diagnosis at which patients are correctly identified as belonging to the
refractory group. We emphasize that these two measures are calculated using those patients who were
truly refractory and also predicted to be refractory by the model. The lead times shown in Table 5 consider
those patients who are truly in the refractory group and are predicted to be in the refractory group. For
the dynamic marginal prediction method, the lead time is 651 days. This means that we can identify
those patients who will not achieve remission from seizures almost two years before they are clinically
observed as such on average. This is a good time gain, allowing clinicians to consider other forms of
treatment, so that patients do not have to endure the adverse side effects of unsuitable treatments.
We now further explore the dynamic LoDA scheme. We chose one of the 100 splits of data into
training and test sets. We chose a split such that the sensitivity and specificity were close to the average
sensitivities and specificities over the 100 splits. Using a cutoff of 0.74 (determined to be optimal for
the marginal prediction, see Table 5), patients were predicted as either refractory or remission using our
proposed allocation scheme. The profiles of patients assigned to each of the remission and refractory
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Table 5. Summary of the classification accuracy for each of the marginal, conditional and random effects
methods and for traditional LDA and QDA. These results are based on averages across 100 splits of the data
into training and test sets. For the dynamic LoDA (first three columns), prediction stops if a patient is predicted
as refractory whilst for full data predictions (Columns 4-6), all data up until the visit before the group status is
confirmed is used in the prediction. The final two columns present the results of prediction using LDA and QDA
based on baseline characteristics and using no longitudinal information.
Marginal Conditional Random effects Marginal Conditional Random effects LDA QDA
(full data) (full data) (full data)
Cutoff 0.74 0.44 0.27 0.52 0.22 0.16 0.17 0.33
Sensitivity 0.94 0.91 0.82 0.93 0.93 0.84 0.80 0.80
Specificity 0.92 0.91 0.72 0.94 0.92 0.80 0.74 0.74
PCC 0.92 0.91 0.73 0.94 0.92 0.80 0.74 0.75
AUC 0.97 0.96 0.83 0.96 0.95 0.89 0.76 0.48
PPV 0.59 0.56 0.26 0.65 0.59 0.34 0.26 0.27
NPV 0.99 0.99 0.97 0.99 0.99 0.98 0.97 0.97
Mean Lead Time (days) 651 634 1000 75 78 65
Mean Prediction Time (days) 876 899 522 1450 1451 1459
groups based on a marginal prediction scheme are shown in Figure 3. Refractory patients that are
misclassified as remission cases (3 patients, top row) have low probabilities. This was due to infrequent
seizures and generally low numbers of seizures.
Most of the patients who are predicted correctly as refractory have high probabilities almost
immediately of being in the refractory group. These are identified early which is consistent with the
good lead times achieved, as shown in Table 5. Some of the patients who are truly refractory but were
classed as remission could be correctly classified by lowering the cutoff (e.g., to 0.5). However, this
would be at the cost of increasing the misclassification rate of remission cases.
In the bottom row of Figure 3, the true remission cases are shown. Most of the patients correctly
identified as being in the remission group have high probabilities of being in the remission group very
early on. Those patients who are wrongly predicted as refractory are generally those who have been
observed for longer and hence taken longer to achieve remission. Such patients may initially have high
numbers of seizures and so have initially high probabilities of being in the refractory group. A limitation
of our allocation scheme is that these patients would be classed as refractory and then prediction would
stop for these patients. It is possible that if they were observed for longer, their probabilities of being in the
remission group would increase. This is a limitation with any classification scheme where an intervention
is planned following a positive result.
4.4 Which longitudinal biomarkers to use
The longitudinal biomarkers we consider in our model are clearly correlated. In particular there is a high
degree of correlation between the binary biomarker describing whether a patient experienced seizures
or not and the continuous biomarker describing how many seizures they experienced. The three markers
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Figure 3. Changes of marginal group membership probabilities over time. The profiles are from one test set of
30% of patients. Their probabilities are calculated using the model developed on the remaining 70% of
patients. The top row shows those patients whose true status is refractory whilst the bottom row shows the
true remission patients. The left hand panels shows all patients who are classed as remission within 5 years.
The right panels shows the patients who are predicted as refractory (up until the point at which they are
classified as refractory)
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Table 6. Comparison of possible models under the marginal prediction scheme based on averages of 100
splits of the data into training and test sets. Y1 denotes whether a patient experienced seizures or not since the
previous visit, Y2 describes the total number of seizures experienced since the previous visit under the
transformation log(1 + total seizures) and Y3 describes the number of adverse events experienced since the
previous visit. The optimal cutoffs for each model were determined by ROC analysis by selecting the top left
most point of the ROC curve.
Cutoff Sensitivity Specificity PCC AUC PPV NPV Mean Lead Mean Prediction
Time (days) Time (days)
Y1 0.61 0.94 0.94 0.94 0.98 0.64 0.99 502 1041
Y2 0.43 0.89 0.87 0.87 0.94 0.45 0.99 860 666
Y3 0.13 0.71 0.69 0.70 0.78 0.22 0.95 1001 535
Y1 + Y2 0.75 0.93 0.92 0.92 0.97 0.57 0.99 656 871
Y1 + Y3 0.54 0.94 0.92 0.92 0.97 0.58 0.99 593 952
Y2 + Y3 0.45 0.90 0.89 0.89 0.95 0.49 0.99 834 692
Y1 + Y2 + Y3 0.72 0.94 0.92 0.92 0.97 0.58 0.99 659 869
were chosen to illustrate different types of longitudinal marker. In this section we investigate what effect
adding or removing any of the three biomarkers has on the predictive accuracy. Under the same procedure
of splitting the data into training and test sets 100 times and averaging the predictive accuracy measures,
we compared each of the combinations of the three longitudinal biomarkers considered in this paper and
present the results in Table 6.
The predictive accuracy of the univariate model involving the binary variable, Seizures, is comparable
to the predictive accuracy of the trivariate model. However, with the trivariate model patients can be
correctly identified approximately five months earlier. So in our example, considering multiple markers
does not improve the predictive accuracy, but does add information that allows prediction of refractory
patients to be made earlier than by simply considering a single biomarker.
4.5 Benefits of dynamic LoDA
Dynamic LoDA has received increased attention in recent years in the statistical literature. It has become
very desirable to have methods of prediction that can be updated at each time point. The alternative to this
is to wait until all the data are gathered and then make a prediction. In our application, this would involve
waiting for almost 5 years in order to determine patients’ status. Obviously, in this scenario, there would
be no need for classification methods since we would simply have observed which group patients belong
to. We would have no misclassification but at the cost of giving some patients ineffective treatment for
potentially 5 years.
By contrast, with our dynamic allocation scheme, the risk is that a patient could have been wrongly
classified as refractory, when if followed up a bit longer they would have been classified as remission.
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It is commonly thought that observing a patient for longer leads to increased information and so
increased accuracy in prediction. We explored this in our example, by comparing the prediction results
in the first three columns of Table 5 with those obtained by using all information gathered on a patient
up until the visit before their status was confirmed (Columns 4-6 of Table 5). In this setting we use all
available longitudinal information for each patient. The benefit of waiting until all information is gathered
is a small increase in the PCC and specificity, while no benefit is observed in sensitivity or AUC for the
marginal prediction (Table 5 and Figure 4). The most evident advantage of the dynamic LoDA over the
use of the full data is the significant difference in lead times and prediction times. By waiting for all the
data to be collected patients would have to wait more than two years extra to be classified, whilst only
making a minimal gain in predictive accuracy.
At the other extreme, an alternative would be to simply predict a patients group membership at
diagnosis, based on various baseline characteristics and take no account of accumulating longitudinal
information. We examined this possibility using traditional linear and quadratic discriminant analysis
methods (LDA and QDA see Hastie et al.10, Chapter 4). These results, also based on 100 splits of the
data into training and test sets, are presented in the final two columns of Table 5. Although reasonably
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Figure 4. Receiver Operating Characteristic curves of the prediction using the marginal (solid red), conditional
(dashed blue) and random effects (dot dashed green) prediction methods. The thick lines represent the
dynamic allocations whilst the thin lines represent the use of the full data.
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accurate prediction can be made at diagnosis, significant improvements in predictive accuracy can be
obtained by updating predictions as new information becomes available for each patient.
In this section we show that there is merit in considering how a patient’s clinical data change over
time during observation and updating the prediction of their five year status each time new information
is available. In addition, we have shown that allocating a patient to the refractory group as soon as their
probability of being in the refractory group rises above a cutoff (as opposed to observing the patient for
five years) does not decrease the predictive accuracy and allows refractory patients to be identified much
earlier on.
5 Discussion
In this paper we propose a time-dependent discriminant analysis approach that allows for the inclusion of
multiple longitudinal biomarkers of various types. Binary, Poisson and continuous longitudinal markers
can be included within a multivariate generalized linear mixed model. An implementation of the methods
described in this paper has now been added to the package mixAK30 of the R software31.
The longitudinal profiles of considered biomarkers are described using generalized linear mixed
models. We have allowed for extra flexibility through the inclusion of a mixture distribution of the
random effects. These random effects capture the correlation between markers and between observations
of a particular marker.
In the clinical application with SANAD data, the inclusion of a normal mixture for the random effects
distribution showed only a mild impact in classification accuracy. Nevertheless, the impact can in general
be much more considerable. An example of such situation is when one of the groups is characterized
by subdivisions of different longitudinal behavior of the considered markers. This subdivision might not
be of interest for classification, nevertheless, if properly taken into account, e.g., by assuming a mixture
distribution for random effects, it may considerably improve the classification accuracy. Moreover, since
mixtures are in general considered as a suitable semi-parametric models for unknown distributions, they
are more able to adapt to model misspecification, and so should be considered as a way of limiting the
effect of model misspecification. In addition to reducing the chances of model misspecification, including
mixtures may in some cases improve the fit of the model by reducing measures such as the penalized
expected deviance. Checking improvement of model fit, and in predictive accuracy will determine if this
methodology will be a useful tool in any particular example.
In our context, the SANAD database which has more than 1 700 patients allowed us to fit reasonable
complex models containing three longitudinal markers and six covariates for each of them. We must point
out that if very small sample sizes were available then more simple models may need to be considered.
Some insight into how large sample is needed to fit models of given complexity can be gained from
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Koma´rek and Koma´rkova´29 who present results of a simulation study towards properties of the estimators
of parameters of the MGLMM that is behind our LoDA procedure.
One of the limitations in our application is that once a patient has achieved remission the follow-
up data after achieving remission are discarded. This has a direct effect on the length of follow up for
some patients in the remission group, although conceptually one could argue that only the profile of the
longitudinal biomarkers before achieving remission are of interest. A possible consequence of this is that
the longitudinal profile of remission patients at late time points may be less accurately estimated since
fewer remission patients are observed for that long. The limitation from a clinical point of view is that
relapse in patients with epilepsy after achieving remission is not considered here.
Using longitudinal information along with dynamic LoDA schemes has been seen to give good
classification results, yielding good prediction accuracy. In addition, we are able to make predictions
about patients substantially earlier than is currently possible showing the potential benefits of such an
approach.
With our dynamic classification scheme used for the SANAD application, we dynamically update
the allocation probabilities as new longitudinal information arrives, nevertheless, prediction of the group
pertinence is performed for each patient only once. Indeed, each patient remains unclassified till either his
allocation probability of being refractory exceeds the cutoff value or those allocation probabilities remain
below the cutoff value for a predefined period of time (five years in our case). Consequently, standard
accuracy measures (such as AUC, sensitivity, specificity, etc.) were applied to evaluate discrimination
ability of our procedure. Alternatively, at each visit, we could have used the allocation probabilities and
predicted the group allocation. This would then also possibly change dynamically over time and different
approach would have to be taken to evaluate a discriminant ability of the LoDA procedure. To this end,
one could adopt an extended definition of sensitivity, specificity, and dynamic AUC as proposed by
Heagerty and Zheng36 in context of survival analysis and then further generalized in different contexts37.
Nevertheless, since our main focus here was ultimately on identifying refractory patients at any point
within the five year period we do not pursue this idea further in this paper.
We compared three approaches to prediction, namely marginal, conditional and random effects
prediction and found that for our application both the marginal and the conditional approaches gave
good prediction, with the marginal approach most often being the best. The random effects prediction
was less accurate for the SANAD data.
We believe our methods could be used in a wide variety of applications. They allow for irregularly
collected data, multivariate longitudinal data and can incorporate data of different types. Classification
into prognostic groups based on biomarker evolution is an increasingly important aspect of clinical
practice and the approach proposed here has the flexibility to be used with many different clinical
biomarkers, increasing the options available to researchers. A useful extension to this work would be to
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allow for discrimination using genuine categorical or ordinal biomarkers. To this end, suitable regression
models suggested recently in the literature38;39 for such outcomes could be considered.
In this paper we present an example where patients are classified into one of two groups. However,
the methods here presented are applicable for classification into three or more groups as, for example,
in applications where the aim is to classify patients into various stages of cancer (as opposed to simply
cancer against cancer free patients) giving wider applicability to the methods proposed.
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